Type I Interferon Upregulates Bak and Contributes to T Cell Loss during Human Immunodeficiency Virus (HIV) Infection
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Type I Interferon Upregulates Bak and Contributes to T Cell Loss during Human Immunodeficiency Virus (HIV) Infection
Authors
Keywords
T cells, Apoptosis, HIV-1, Cytotoxic T cells, SIV, Viral load, Flow cytometry, Small interfering RNAs
Journal
PLoS Pathogens
Volume 9, Issue 10, Pages e1003658
Publisher
Public Library of Science (PLoS)
Online
2013-10-12
DOI
10.1371/journal.ppat.1003658
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
- (2013) E. B. Wilson et al. SCIENCE
- An Interferon Paradox
- (2013) P. M. Odorizzi et al. SCIENCE
- Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling
- (2013) J. R. Teijaro et al. SCIENCE
- Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation
- (2012) T. H. Vanderford et al. BLOOD
- Regulation of CD95/Fas signaling at the DISC
- (2011) I N Lavrik et al. CELL DEATH AND DIFFERENTIATION
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- CD4+ T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD4+ T Cells
- (2011) Sonia Fernandez et al. JOURNAL OF INFECTIOUS DISEASES
- Phosphorothioate 2' Deoxyribose Oligomers as Microbicides That Inhibit Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Block Toll-Like Receptor 7 (TLR7) and TLR9 Triggering by HIV-1
- (2010) J. A. Fraietta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interleukin-7 treatment counteracts IFN- therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques
- (2010) R. Parker et al. BLOOD
- Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial
- (2010) David M. Asmuth et al. JOURNAL OF INFECTIOUS DISEASES
- Interferon-Alpha Mediates Restriction of Human Immunodeficiency Virus Type-1 Replication in Primary Human Macrophages at an Early Stage of Replication
- (2010) Kelly M. Cheney et al. PLoS One
- Inability of Plasmacytoid Dendritic Cells To Directly Lyse HIV-Infected Autologous CD4+ T Cells despite Induction of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
- (2009) J. Chehimi et al. JOURNAL OF VIROLOGY
- Off-Target Analysis of Control siRNA Molecules Reveals Important Differences in the Cytokine Profile and Inflammation Response of Human Fibroblasts
- (2009) Patrick Baum et al. OLIGONUCLEOTIDES
- Transcriptional Profiling in Pathogenic and Non-Pathogenic SIV Infections Reveals Significant Distinctions in Kinetics and Tissue Compartmentalization
- (2009) Sharon Lederer et al. PLoS Pathogens
- Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression
- (2008) B. Malleret et al. BLOOD
- The DNA Sugar Backbone 2′ Deoxyribose Determines Toll-like Receptor 9 Activation
- (2008) Tobias Haas et al. IMMUNITY
- Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections
- (2008) Judith N Mandl et al. NATURE MEDICINE
- Beneficial Effect of TRAIL on HIV Burden, without Detectable Immune Consequences
- (2008) Brett D. Shepard et al. PLoS One
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started